$REGN News
Last published 3d ago
- 3d agoREGNCIDEB siRNA Normalizes Liver Fat and Improves Liver Injury Markers in MASLD Patients, as Highlighted at AASLDGlobeNewswireSingle administration of CIDEBsiRNA resulted in rapid, deep and durable reductions in liver fat by up to 80% that were sustained through 36 weeks Data...
- 3d agoREGNCIDEB siRNA Normalizes Liver Fat and Improves Liver Injury Markers in MASLD Patients, as Highlighted at AASLDGlobeNewswireSingle administration of CIDEBsiRNA resulted in rapid, deep and durable reductions in liver fat by up to 80% that were sustained through 36 weeks Data from first-in-human trial were shared in oral presentation at AASLD
- 1w agoREGNRegeneron Announces Investor Conference PresentationsGlobeNewswireTARRYTOWN, N.Y., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: 2026 Jefferies Global Healthcare Conference in London at 2:00 p.m.
- 1w agoREGNRegeneron Pharmaceuticals Q3 2026 Earnings Conference Call - REGENERON PHARMACEUTICALS INCEarnings Call TranscriptsWelcome to the Regeneron Pharmaceuticals 3rd Quarter 2026 Earnings Conference Call. My name is Shannon, and I'll be your operator for today's call. At this time, all participants are in a listen-only mode. Later, we will
- 1w agoREGNREGENERON PHARMACEUTICALS, INC. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoREGNRegeneron Reports Third Quarter 2026 Financial and Operating ResultsGlobeNewswireThird quarter 2026 revenues increased 36% to $5.1 billion versus third quarter 2025Dupixent® global net sales (recorded by Sanofi) increased 35% to $6.5 billionEYLEA HD® U.S. net sales increased 62% to
- 2w agoREGNRegeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. PreparednessGlobeNewswireUpdated agreement expands 2020 procurement agreement with BARDA for Regeneron's first-in-class antibody treatment for Orthoebolavirus zairense, adding value of approximately $270 million TARRYTOWN, N.Y., Oct. 26,
- 2w agoREGNLibtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)GlobeNewswireLonger-term data reflecting nearly 4 years of follow-up show a further reduction in the risk of death from 14% to 37% for those initially treated with Libtayo, despite an 88% crossover from the placebo arm upon
- 3w agoREGNLibtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer TypesGlobeNewswirePositive opinion supports reducing Libtayo dosing frequency from every three weeks to every six weeks after first 12 weeks of treatment Optional reduction of infusion time for 350 mg dose to 15 to 30 minutes, after a
- 1mo agoREGNPasatru™ (garetosmab-grts) Demonstrates Zero New Heterotopic Ossification (HO) Lesions in Adult Fibrodysplasia Ossificans Progressiva (FOP) Patients During OPTIMA Trial ExtensionGlobeNewswirePasatru is the first and only FDA-approved treatment demonstrating reductions in both new HO lesions and clinician-assessed flare-ups, per results of a 56-week placebo-controlled trial in adults with FOP Late-breaking
- 1mo agoREGNREGPHARegeneron & Sanofi Investor Event - REGENERON PHARMACEUTICALS INCEarnings Call TranscriptsRegeneron and Sanofi joint conference call announcing their expanded collaboration to include next generation type 2 medicines. My name is Michelle and I'll be your operator for today's call. At this time, all participan
- 1mo agoREGNREGPHABernstein Insights Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum - REGENERON PHARMACEUTICALS INCEarnings Call TranscriptsThank you so much for our next conversation with healthcare leaders and disruptors. I have the pleasure of speaking with Regeneron Pharmaceuticals. My name is Jeffrey Walsh. I'm one of the analysts at Bernstein. I cover
- 1mo agoREGNREGPHABERNSTEIN INSIGHTS HEALTHCARE LEADERS AND DISRUPTORS - 3RD ANNUAL HEALTHCARE FORUM - REGENERON PHARMACEUTICALS INCEarnings Call TranscriptsThank you so much for our next conversation with healthcare leaders and disruptors. I have the pleasure of speaking with Regeneron Pharmaceuticals. My name is Jeffrey Walsh. I'm one of the analysts at Bernstein. I cover
- 1mo agoREGNREGPHAMorgan Stanley 24th Annual Global Healthcare Conference - REGENERON PHARMACEUTICALS INCEarnings Call TranscriptsAll right. Good afternoon, everybody. Thanks for joining us. I'm Terrence Flynn, Morgan Stanley's U.S. Biopharma Analyst. For important disclosures, please see the Morgan Stanley Research Disclosure website at www.morgan
- 2mo agoREGNREGPHAWells Fargo 21st Annual Healthcare Conference - REGENERON PHARMACEUTICALS INCEarnings Call Transcriptswelcome welcome welcome my name is Mohit Bansal I'm one of the biotech and pharma analyst here at Wells Fargo and I have the pleasure to start the day with the Regeneron management team fifth year in a row yeah my five y
- 2mo agoREGNREGPHAWells Fargo 21st Annual Healthcare Conference - REGENERON PHARMACEUTICALS INCEarnings Call Transcriptswelcome welcome welcome my name is Mohit Bansal I'm one of the biotech and pharma analyst here at Wells Fargo and I have the pleasure to start the day with the Regeneron management team fifth year in a row yeah my five y
- 2mo agoAZNREGNSNYGSKAstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopesCNBCThe full data reinforces hopes that the drug could be a breakthrough COPD treatment and reach AstraZeneca's peak annual sales forecast of more than $5 billion.
- 2mo agoREGNRegeneron Announces Investor Conference PresentationsGlobeNewswireTARRYTOWN, N.Y., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: 2026 Wells Fargo Healthcare Conference at 8:45 a.m. ET on
- 2mo agoREGNPasatru™ (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial in Adults with Fibrodysplasia Ossificans Progressiva (FOP)GlobeNewswireFOP is an ultra-rare genetic disorder characterized by rogue bone formation that infiltrates muscles, tendons, ligaments and other connective tissues, resulting in significant disability Approval based on results from
- 2mo agoREGNApproval of Pasatru, Bla #761508FDA Approved DrugsApproval Date: 08/19/2026; Drug Name: Pasatru, Bla #761508; Active Ingredients: GARETOSMAB; Company: Regeneron Pharmaceuticals, Inc; Submission Status: Approval; Application Number: 761508
- 3mo agoREGNThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 14, 2026 in Regeneron Pharmaceuticals, Inc. Lawsuit - REGNPR NewswireThe Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). Shareholders who purchased shares...
- 3mo agoREGNRegeneron Awards $150,000 to Winners of the 2026 Regeneron Prize for Creative InnovationGlobeNewswireEarly-career scientists from New York University, Stanford University and Rensselaer Polytechnic Institute were recognized for their ambitious "dream project" proposals TARRYTOWN, N.Y., July 31, 2026 (GLOBE
- 3mo agoREGNREGPHARegeneron Pharmaceuticals Q2 2026 Earnings Conference Call - REGENERON PHARMACEUTICALS INCEarnings Call TranscriptsThis video tutorial shows how to install Kali Linux 2017.1 LXDE on VMware Workstation or VMware Workspace. Kali LXD is a very simple and easy-to-use software that can be installed on your computer. To install it, click o
- 3mo agoREGNRegeneron Reports Second Quarter 2026 Financial and Operating ResultsGlobeNewswireSecond quarter 2026 revenues increased 17% to $4.3 billion versus second quarter 2025Dupixent® global net sales (recorded by Sanofi) increased 38% to a new all-time high of $6.0 billion EYLEA HD® U.S. net sales
- 3mo agoREGNThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 14, 2026 in Regeneron Pharmaceuticals, Inc. Lawsuit - REGNGlobeNewswireNEW YORK, July 24, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Shareholders who purchased shares of REGN during the class
- 3mo agoREGNMRKTessera Therapeutics Appoints Joseph Romanelli as President and Chief Executive OfficerPR NewswireTessera Therapeutics ("Tessera"), the biotechnology company pioneering a new approach to genetic medicine known as Gene Writing™, today announced the ...
- 3mo agoREGNApproval of Dupixent, Bla #761055FDA Approved DrugsApproval Date: 07/15/2026; Drug Name: Dupixent, Bla #761055; Active Ingredients: DUPILUMAB; Company: Regeneron Pharmaceuticals; Submission Status: Approval; Application Number: 761055
- 4mo ago.DJI.RUT.SPX.IXIC+9SCOTUS decisions, Dow at 52,000, the retirement savings gap and more in Morning SquawkCNBCHere are five key things investors need to know to start the trading day.
- 4mo agoAMRXREGNFDA Selects Seven Participants for PreCheck Pilot Program to Advance U.S. Drug ManufacturingFDA Press ReleasesToday, the U.S. Food and Drug Administration announced the selection of seven companies to participate in the FDA PreCheck Pilot Program, a new initiative designed to boost American global competitiveness, strengthen domestic drug manufacturing, and improve the resilience of the U.S. drug supply chain.The FDA launched the PreCheck Pilot Program on February 1, 2026, in response to Executive Order 1 ...
- 4mo agoREGNCemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)GlobeNewswireCemdisiran could be the first siRNA approved for the treatment of gMG and only therapy to be offered subcutaneously with four times a year dosing FDA accepted NDA under Priority Review with a target action date in
- 5mo agoREGNREGPHAAnnual Meeting of Shareholders - REGENERON PHARMACEUTICALS INCEarnings Call TranscriptsGood morning and welcome to the 2026 Annual Shareholder Meeting of Regeneron Pharmaceuticals. The meeting will begin after the following message. you you you you you The meeting proceedings will now begin. Good morning,
- 5mo agoREGNRegeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDOGlobeNewswireTARRYTOWN, N.Y., June 04, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced that new clinical data and research from its metabolic disease, ophthalmology and rare disease pipelines
- 5mo agoREGNRegeneron's Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus OutbreakGlobeNewswireInmazeb® (a three-antibody cocktail consisting of maftivimab, atoltivimab and odesivimab-ebgn) was the first Ebola treatment approved by the U.S. Food and Drug Administration, indicated specifically for the
- 5mo agoCVLTMDBNUAIREGNNotice to Long-Term Shareholders of Commvault Systems, Inc. (NASDAQ: CVLT); MongoDB, Inc. (NASDAQ: MDB); New Era Energy & Digital, Inc. (NASDAQ: NUAI); and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN): Grabar Law Office is Investigating Claims on Your BehalfGlobeNewswirePHILADELPHIA, May 27, 2026 (GLOBE NEWSWIRE) -- Commvault Systems, Inc. (NASDAQ:CVLT): Grabar Law Office is investigating claims on behalf of shareholders of Commvault Systems, Inc. (NASDAQ:CVLT). The investigation
- 5mo agoREGNOtarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing LossGlobeNewswireTARRYTOWN, N.Y., May 22, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced the European Medicines Agency (EMA) has accepted for review under Accelerated Assessment the Marketing
- 5mo agoREGNLynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain AmyloidosisGlobeNewswireNormalization of free light chains occurred by day 15 across all doses 100% of patients achieved a hematologic complete response (CR) at the highest tested dose Majority of patients with renal or cardiac involvement
- 5mo agoREGNRegeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic AreasGlobeNewswireThe multi-target collaboration combines Regeneron's industry-leading antibody capabilities with Parabilis' novel Helicon™ peptide platform Agreement provides for Parabilis to receive $125M from Regeneron,
- 5mo agoREGNRegeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic MelanomaGlobeNewswireThe trial did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS) A numeric improvement of 5.1 months in median PFS was observed for the high-dose fianlimab
- 6mo agoREGNUPDATE – Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering FairGlobeNewswireTARRYTOWN, N.Y. and WASHINGTON, May 15, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc., and Society for Science (the Society) announced that Hikaru Kuribayashi, 17, of Sapporo, Japan won the $100,000 George
- 6mo agoREGNNext Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering FairGlobeNewswireHikaru Kuribayashi, 17, receives $100,000 Top Award for his creation of a simulation program to understand complex folding at the world's largest pre-college STEM competition. TARRYTOWN, N.Y. and WASHINGTON, May 15,
- 6mo agoHCWBMRNAREGNBiologics Market Momentum Accelerates Across Healthcare, AI, And Global Medical TourismGlobeNewswireDENVER, May 15, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) - The biologics sector is rapidly emerging as one of the most closely watched growth stories in healthcare as breakthroughs in immunotherapy, regenerative
- 6mo agoREGNRegeneron Named to Dow Jones Best-in-Class World Index for Global Responsibility Leadership for Seven Consecutive YearsGlobeNewswireRegeneron also earns spot on Dow Jones Best-in-Class North America Index for six consecutive years Recognition complements the company's recent announcement that it will provide its new gene therapy for a form of
- 6mo agoLLYNTHINVOREGNBiotech's Next Wave May Already be in MotionGlobeNewswireDENVER, May 07, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com and NeOnc Technology) - The biotech and pharma sector is entering one of its most pivotal periods in years, where insider conviction, late-stage clinical
- 6mo agoREGNDupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 TrialGlobeNewswireDupixent showed significant and clinically meaningful improvements in both esophageal distensibility as well as disease-related structural changes and inflammation in the esophagus in adult patients with EoE at week 24
- 6mo agoREGNRegeneron Reports First Quarter 2026 Financial and Operating ResultsGlobeNewswireFirst quarter 2026 revenues increased 19% to $3.6 billion versus first quarter 2025Dupixent® global net sales (recorded by Sanofi) increased 33% to $4.9 billion EYLEA HD® U.S. net sales increased 52% to
- 6mo agoREGNRegeneron weighs overseas price for Otarmeni, gene therapy for rare type of hearing lossCNBCRegeneron will make its newly approved gene therapy available for free in the U.S. The company hasn't yet decided how much it will charge in other countries.
- 6mo ago.IXICNOWIBMTSLA+7Israel-Lebanon ceasefire, Microsoft's first-ever buyouts, Starbucks' loyalty program and more in Morning SquawkCNBCHere are five key things investors need to know to start the trading day.
- 6mo agoREGNRegeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S.GlobeNewswireRegeneron will provide Otarmeni™ (lunsotogene parvec-cwha), its recently approved gene therapy for an ultra-rare form of genetic hearing loss, for free in the U.S. Regeneron will lower Medicaid prices based on
- 6mo agoREGNRegeneron inks drug pricing deal with Trump, will offer new hearing-loss therapy for freeCNBCRegeneron is the latest in a string of major drugmakers to make pricing concessions for new and existing medicines under agreements with Trump.
- 6mo agoREGNOtarmeni™ (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S.GlobeNewswireApproval in severe-to-profound and profound OTOF-related hearing loss is based on pivotal results of the CHORD trial demonstrating 80% of participants achieved or surpassed a hearing level meeting the primary endpoint,